Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 255

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH‐based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5‐nations trial

Open access
Hoogma, R. P. L. M., Hammond, P. J., Gomis, R., Kerr, D., Bruttomesso, D., Bouter, K. P., Wiefels, K. J., De La Calle, H., Schweitzer, D. H., Pfohl, M., Torlone, E., Krinelke, L. G., Bolli, G. B., on behalf of the 5‐Nations Study Group·2006·Diabetic Medicine

Abstract

Aims The goal of the study was to determine whether continuous subcutaneous insulin infusion (CSII) differs from a multiple daily injection (MDI) regimen based on neutral protamine hagedorn (NPH) as basal insulin with respect to glycaemic control and quality of life in people with Type 1 diabetes. Methods The 5‐Nations trial was a randomized, controlled, crossover trial conducted in 11 European centres. Two hundred and seventy‐two patients were treated with CSII or MDI during a 2‐month run‐in period followed by a 6‐month treatment period, respectively. The quality of glycaemic control was assessed by HbA 1c, blood glucose values, and the frequency of hypoglycaemic events. For the evaluation of the quality of life, three different self‐report questionnaires have been assessed. Results CSII treatment resulted in lower HbA 1c (7.45 vs. 7.67%, P < 0.001), mean blood glucose level (8.6 vs. 9.4 mmol/l, P < 0.001) and less fluctuation in blood glucose levels than MDI (± 3.9 vs. ± 4.3 mmol/l, P < 0.001). There was a marked reduction in the frequency of hypoglycaemic events using CSII compared with MDI, with an incidence ratio of 1.12 [95% confidence interval (CI): 1.08–1.17] and 2.61 (95% CI: 1.59–4.29) for mild and severe hypoglycaemia, respectively. The overall score of the diabetes quality of life questionnaire was higher for CSII (P < 0.001), and an improvement in pump users’ perception of mental health was detected when using the SF‐12 questionnaire (P < 0.05). Conclusion CSII usage offers significant benefits over NPH‐based MDI for individuals with Type 1 diabetes, with improvement in all significant metabolic parameters as well as in patients’ quality of life. Additional studies are needed to compare CSII with glargine‐ and detemir‐based MDI.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2005.01738.x

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 255

Metadata

Authors
Hoogma, R. P. L. M., Hammond, P. J., Gomis, R., Kerr, D., Bruttomesso, D., Bouter, K. P., Wiefels, K. J., De La Calle, H., Schweitzer, D. H., Pfohl, M., Torlone, E., Krinelke, L. G., Bolli, G. B., & on behalf of the 5‐Nations Study Group
Venue
Diabetic Medicine
Publisher
Wiley
Published
2005-08-24
Volume
23
Issue
2
Pages
141-147
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W1968703488
Cited by
255
References
29
FWCI
8.57
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH‐based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5‐nations trial. https://app.cochat.ai/papers/10.1111/j.1464-5491.2005.01738.x
The paper
Hoogma, R. P. L. M., Hammond, P. J., Gomis, R., Kerr, D., Bruttomesso, D., Bouter, K. P., Wiefels, K. J., De La Calle, H., Schweitzer, D. H., Pfohl, M., Torlone, E., Krinelke, L. G., Bolli, G. B., & on behalf of the 5‐Nations Study Group. (2006). Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH‐based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5‐nations trial. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2005.01738.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.